{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:59:47Z","timestamp":1768697987938,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"a Certara Company"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.anai.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T22:57:29Z","timestamp":1533941849000},"page":"568-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma"],"prefix":"10.1016","volume":"121","author":[{"given":"Alexa P.","family":"Kollmeier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elliot S.","family":"Barnathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichuan (Karen)","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Loza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-5199","authenticated-orcid":false,"given":"Philip E.","family":"Silkoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Thurmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.08.001_bib0001","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0091-6749(91)90158-K","article-title":"Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway","volume":"88","author":"Broide","year":"1991","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.08.001_bib0002","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1172\/JCI112937","article-title":"Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness","volume":"79","author":"Casale","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2018.08.001_bib0003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1164\/ajrccm\/144.1.83","article-title":"Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction","volume":"144","author":"Jarjour","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.anai.2018.08.001_bib0004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1164\/ajrccm\/142.1.126","article-title":"Evidence for elevated levels of histamine, prostaglandin D2, and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma","volume":"142","author":"Liu","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.anai.2018.08.001_bib0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1164\/ajrccm\/137.1.62","article-title":"Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity","volume":"137","author":"Wardlaw","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.anai.2018.08.001_bib0006","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1164\/ajrccm\/137.5.1002","article-title":"Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma","volume":"137","author":"Wenzel","year":"1988","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.anai.2018.08.001_bib0007","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/0091-6749(89)90293-5","article-title":"The relationship between plasma histamine concentrations and bronchial obstruction to antigen challenge in allergic rhinitis","volume":"84","author":"Busse","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.08.001_bib0008","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/0091-6749(89)90009-2","article-title":"Spontaneous histamine release and histamine content in normal subjects and subjects with asthma","volume":"83","author":"Akagi","year":"1989","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2018.08.001_bib0009","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2125.1979.tb01010.x","article-title":"Effects of oral H1 and H2 receptor antagonists in asthma","volume":"8","author":"Leopold","year":"1979","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anai.2018.08.001_bib0010","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1365-2125.1984.tb02545.x","article-title":"H2-receptor blockade and exercise-induced asthma","volume":"18","author":"Nogrady","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anai.2018.08.001_bib0011","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1183\/09031936.97.10102216","article-title":"Effects of antihistamines in adult asthma: a meta-analysis of clinical trials","volume":"10","author":"Van Ganse","year":"1997","journal-title":"Eur Respir J"},{"issue":"suppl 2","key":"10.1016\/j.anai.2018.08.001_bib0012","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1007\/s00011-009-0128-1","article-title":"UR-60427, a novel H4 receptor-inverse agonist that shows good efficacy in a rat asthma model","volume":"59","author":"Alfon","year":"2010","journal-title":"Inflamm Res"},{"key":"10.1016\/j.anai.2018.08.001_bib0013","doi-asserted-by":"crossref","first-page":"e30285","DOI":"10.1371\/journal.pone.0030285","article-title":"Opposite effects of mepyramine on JNJ 7777120-induced amelioration of experimentally induced asthma in mice in sensitization and provocation","volume":"7","author":"Beermann","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.anai.2018.08.001_bib0014","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1465-9921-11-86","article-title":"Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokines","volume":"11","author":"Cowden","year":"2010","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2018.08.001_bib0015","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.4049\/jimmunol.176.11.7062","article-title":"The histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4+ T cells","volume":"176","author":"Dunford","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.anai.2018.08.001_bib0016","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/bph.12264","article-title":"A selective antagonist of histamine H4 receptors prevents antigen-induced airway inflammation and bronchoconstriction in guinea pigs: involvement of lipocortin-1","volume":"170","author":"Somma","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.anai.2018.08.001_bib0017","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.113.211714","article-title":"Clinical and preclinical characterization of the histamine H4 receptor antagonist JNJ-39758979","volume":"349","author":"Thurmond","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.anai.2018.08.001_bib0018","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2010.10.065","article-title":"Histamine H4 receptor antagonism inhibits allergen-specific T-cell responses mediated by human dendritic cells","volume":"651","author":"Lundberg","year":"2011","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.anai.2018.08.001_bib0019","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2018.08.001_bib0020","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2018.08.001_bib0021","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2018.08.001_bib0022","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2018.08.001_bib0023","first-page":"1013","article-title":"Pharmacology and clinical activity of toreforant, a histamine H4 receptor antagonist","volume":"2","author":"Thurmond","year":"2017","journal-title":"Ann Pharmacol Pharm"},{"key":"10.1016\/j.anai.2018.08.001_bib0024","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3899\/jrheum.160164","article-title":"Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: results of 2 phase II studies","volume":"43","author":"Thurmond","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.anai.2018.08.001_bib0025","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/cea.13154","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of an H4R-antagonist (JNJ-39758979) in adults with uncontrolled asthma","volume":"48","author":"Kollmeier","year":"2018","journal-title":"Clin Exp Allerg"},{"key":"10.1016\/j.anai.2018.08.001_bib0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/1346-8138.12726","article-title":"Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis","volume":"42","author":"Murata","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.anai.2018.08.001_bib0027","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pupt.2016.06.005","article-title":"The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma","volume":"39","author":"Erpenbeck","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.anai.2018.08.001_bib0028","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2018.08.001_bib0029","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(00)05113-8","article-title":"Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial","volume":"357","author":"Robinson","year":"2001","journal-title":"Lancet"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112061830632X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108112061830632X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:20:21Z","timestamp":1761052821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108112061830632X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S108112061830632X"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.08.001","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}